US Broker Ratings

LENZ Therapeutics, Inc. (LENZ): A Biotech Stock with a Potential Upside of Over 267%

For investors with an eye on the biotechnology sector, LENZ Therapeutics, Inc. (NASDAQ: LENZ) presents an intriguing opportunity. Operating out of Solana Beach, California, this biopharmaceutical company is on the..

Vir Biotechnology, Inc. (VIR) Stock Analysis: Unveiling a 136% Potential Upside Amidst Biotech Challenges

Vir Biotechnology, Inc. (NASDAQ: VIR) is a compelling name in the biopharmaceutical landscape, especially for investors seeking high-risk, high-reward opportunities. As a clinical-stage company, Vir Biotechnology focuses on the discovery..

Eton Pharmaceuticals (ETON): Exploring a 109% Potential Upside with a Strong Buy Consensus

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) has positioned itself as a compelling player in the healthcare sector, specifically within the niche of drug manufacturing for specialty and generic medicines. With a..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating Through a 27% Potential Upside

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) stands out in the biotechnology sector with its innovative contributions to drug and vaccine development. With a market capitalization of $1.13 billion, this San..

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a Potential 286% Upside

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is a name that continues to intrigue investors within the biotechnology sector due to its cutting-edge focus on cell therapies for cancer treatment. With a..

Simulations Plus, Inc. (SLP) Stock Analysis: A Deeper Look at its 74% Potential Upside

Simulations Plus, Inc. (NASDAQ: SLP) stands at the intriguing intersection of healthcare and technology, specializing in cutting-edge software solutions for drug discovery and development. As a prominent player in the..

Arbutus Biopharma (ABUS) Stock Analysis: Unpacking the 56.51% Potential Upside in Biotech Investment

Arbutus Biopharma Corporation (NASDAQ: ABUS) is positioning itself as a compelling player in the biotechnology sector, with a notable focus on developing therapeutics for infectious diseases. Headquartered in Warminster, Pennsylvania,..

Neuropace, Inc. (NPCE) Stock Analysis: Exploring the 25.89% Potential Upside and Analyst Optimism

Investors looking for opportunities in the healthcare sector might find Neuropace, Inc. (NASDAQ: NPCE) a compelling addition to their portfolios. This U.S.-based medical device company, with a market capitalization of..

Ardelyx, Inc. (ARDX) Stock Analysis: Evaluating a 110% Potential Upside with Strong Buy Ratings

Ardelyx, Inc. (NASDAQ: ARDX), a biotechnology company based in Waltham, Massachusetts, is catching the eye of investors with its significant potential upside and unanimous buy ratings from analysts. Specializing in..

AnaptysBio, Inc. (ANAB) Stock Analysis: Exploring a 41.79% Potential Upside in Biotechnology

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company with a market capitalization of $1.34 billion, is capturing investor attention with its significant growth potential in the healthcare sector. Specializing in..

Oculis Holding AG (OCS) Stock Analysis: A Biotech Player with a 65% Upside Potential

Oculis Holding AG (NASDAQ: OCS) is capturing investor attention with its significant growth potential in the biopharmaceutical landscape. With a remarkable potential upside of 65.30%, this Swiss-based biotechnology company is..

Mind Medicine (MNMD) Investor Outlook: Exploring a Potential 90% Upside in the Biotech Arena

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a promising player in the biotechnology sector, is capturing investor attention with its ambitious clinical-stage biopharmaceutical endeavors. Headquartered in New York, MindMed is pioneering..

Akebia Therapeutics, Inc. (AKBA): Investor Outlook on a Biopharma with 262% Upside Potential

Investors seeking high-growth opportunities in the healthcare sector may find Akebia Therapeutics, Inc. (NASDAQ: AKBA) an intriguing prospect. With a focus on developing therapeutics for kidney diseases, Akebia’s innovative portfolio..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Unveiling an 88% Upside Potential in Biotech

For investors seeking promising opportunities in the biotechnology sector, Nurix Therapeutics, Inc. (NASDAQ: NRIX) presents a compelling case with significant upside potential. Currently trading at $15.95, the company boasts an..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a Promising 139.68% Upside Potential

Gyre Therapeutics, Inc. (NASDAQ: GYRE) stands out in the biotechnology sector, promising a substantial potential upside of 139.68% based on current analyst ratings. As investors navigate the dynamic world of..

KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: Unveiling a 134.57% Potential Upside in Biotech Innovation

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is carving a niche in the biotechnology sector with its innovative approach to drug development, focusing on therapies for diseases with unmet needs. Headquartered in..

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring a 155% Potential Upside in the Biotech Sector

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) stands out in the biotechnology sector, attracting significant attention from investors with its compelling potential upside of 155% based on current analyst projections. With a..

Spyre Therapeutics, Inc. (SYRE) Stock Analysis: Biotechnology Innovator with a 71% Upside Potential

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a burgeoning player in the biotechnology sector, is capturing investor attention with its promising therapeutic developments aimed at combating inflammatory bowel disease (IBD). With a..

Avanos Medical, Inc. (AVNS) Stock Analysis: A Healthcare Play with a Focus on Innovative Pain Solutions

Avanos Medical, Inc. (NYSE: AVNS), a prominent player in the healthcare sector, specifically in the medical devices industry, is attracting attention with its innovative approach to pain management and digestive..

Nutex Health Inc. (NUTX) Stock Analysis: A 145% Upside Potential with Strong Analyst Support

For investors scanning the healthcare sector for promising opportunities, Nutex Health Inc. (NUTX) stands out with a compelling blend of robust revenue growth and substantial upside potential. Operating within the..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds